Abbott Laboratories (NYSE:ABT) Issues Earnings Results, Meets Estimates

Abbott Laboratories (NYSE:ABT) posted its earnings results on Thursday. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50, FiscalAI reports. The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The firm’s revenue was up 4.4% compared to the same quarter last year. During the same period last year, the firm earned $1.34 EPS.

Abbott Laboratories Price Performance

NYSE ABT opened at $120.82 on Thursday. Abbott Laboratories has a 1 year low of $113.50 and a 1 year high of $141.23. The business’s fifty day moving average is $125.65 and its two-hundred day moving average is $128.68. The stock has a market capitalization of $210.10 billion, a P/E ratio of 15.14, a P/E/G ratio of 2.01 and a beta of 0.72. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be issued a $0.63 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio is currently 31.58%.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Management issued 2026 guidance calling for 6.5%–7.5% organic sales growth and adjusted diluted EPS of $5.55–$5.80 (?10% growth at the midpoint), which signals confidence in recovery and future earnings growth. Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
• Positive Sentiment: Abbott received CE mark in Europe for the TactiFlex Duo ablation catheter, expanding its AFib device portfolio and supporting medtech growth in Europe. Abbott receives CE Mark for the TactiFlex Duo Ablation Catheter
• Positive Sentiment: Coverage pieces highlight Abbott’s steady dividend history and durable businesses (medical devices and diagnostics), supporting its appeal to income-focused investors. Want Decades of Passive Income? 2 Stocks to Buy.
• Neutral Sentiment: Q4 adjusted EPS of $1.50 matched analyst consensus (GAAP EPS $1.01); full-year 2025 adjusted EPS was $5.15 — earnings met expectations but offered limited upside surprise. Abbott Laboratories Trading Down 0.3%
• Neutral Sentiment: Analysts and previews were active around Q4 results, with some firms revising models ahead of the release — implies increased scrutiny but no consensus catalyst. Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings
• Negative Sentiment: Revenue missed estimates due to weakness in the diagnostics segment — ongoing volatility from lower COVID-19 testing demand and a reported freeze on foreign aid weighed on top-line results. This is the main near-term driver of selling pressure. Abbott misses quarterly revenue estimates on weakness in diagnostics segment

Institutional Investors Weigh In On Abbott Laboratories

Several hedge funds have recently modified their holdings of ABT. Turning Point Benefit Group Inc. bought a new position in Abbott Laboratories in the 3rd quarter worth approximately $39,000. Triumph Capital Management acquired a new stake in shares of Abbott Laboratories in the third quarter worth $92,000. FSA Wealth Management LLC increased its position in Abbott Laboratories by 12.9% during the third quarter. FSA Wealth Management LLC now owns 885 shares of the healthcare product maker’s stock worth $119,000 after acquiring an additional 101 shares during the period. Riggs Asset Managment Co. Inc. raised its stake in Abbott Laboratories by 9.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock valued at $140,000 after purchasing an additional 88 shares during the last quarter. Finally, McIlrath & Eck LLC boosted its holdings in Abbott Laboratories by 16.0% in the 2nd quarter. McIlrath & Eck LLC now owns 1,122 shares of the healthcare product maker’s stock valued at $153,000 after purchasing an additional 155 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Barclays raised their price target on Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a report on Monday, January 5th. The Goldman Sachs Group lowered their target price on shares of Abbott Laboratories from $157.00 to $152.00 and set a “buy” rating on the stock in a research note on Friday, January 9th. Evercore ISI upped their price target on shares of Abbott Laboratories from $142.00 to $144.00 and gave the stock an “outperform” rating in a research note on Monday, January 5th. Royal Bank Of Canada reiterated an “outperform” rating and set a $147.00 price objective on shares of Abbott Laboratories in a research note on Thursday, October 16th. Finally, Daiwa Capital Markets upped their target price on Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $147.42.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.